

Explore by topic
2026 — Full-year results 2025 published; focus on NIVEA rebalancing and Derma expansion
Beiersdorf published its 2025 annual results in early March 2026 and set 2026 priorities: rebalancing the NIVEA portfolio, further expanding Derma, and strengthening Luxury. The Supervisory Board approved the 2025 financial statements.
Investors viewed Beiersdorf as resilient in a slowing market. Group growth slowed versus 2023 but profitability held. Market perception shifted from the rapid growth narrative of 2022–2024 toward a more nuanced view emphasizing portfolio rebalancing (NIVEA), continued Derma outperformance, and selective luxury recovery. Management framed 2026 as a year of targeted course corrections.
Group sales reached €9,852 million in 2025. Organic sales growth was 2.4%. EBIT excluding special factors came to €1,378 million with an EBIT margin of 14.0% [1][3][9].
August 3, 2026 — Half-year 2026: Derma outperformance; NIVEA turnaround plan; guidance adjusted and new buyback program announced
Beiersdorf reported H1 2026 results on August 3, 2026. The company announced an 18-month turnaround and rebalancing plan for NIVEA, adjusted full-year guidance, and approved a new share buyback program as part of capital allocation.
The market regarded Beiersdorf as addressing brand-specific weakness (NIVEA) while leaning on structurally strong Derma brands. The buyback signaled management confidence in cash generation and supported shareholder returns amid near-term sales pressure.
H1 2026 group sales reached approximately €5.0 billion. Organic group sales declined 3.5%. Consumer organic declined 4.0%. EBIT excluding special factors came to €768 million with an EBIT margin of 15.5% [13][14].
October 27, 2026 — Third quarter 2026: Derma and La Prairie acceleration; NIVEA improving vs Q2; guidance confirmed
Q3 2026 results released on October 27, 2026 showed continued Derma strength, accelerating La Prairie performance, and improving net-sales dynamics for NIVEA versus H1. The company confirmed full-year 2026 guidance.
Investors viewed the execution of the NIVEA rebalancing and the Derma growth strategy as beginning to stabilize revenue trends. Confirmation of guidance reduced short-term uncertainty.
Q3 2026 group net sales reached €2.4 billion. Q3 organic sales declined 1.3%. First nine months group net sales came to €7.3 billion with an organic decline of 2.8% [6][15].
2025 — Product innovation and launches; NIVEA CELLULAR Epicelline rollout; record Derma rollouts
Beiersdorf launched major new innovations including Epicelline® introduced to the mass market and NIVEA CELLULAR Epigenetics Rejuvenating Serum. The company continued rollouts of Derma actives (Thiamidol®, Epicelline®) across key markets.
The company emphasized innovation-led premiumization in face care and Derma science to drive higher-margin growth. Investors saw product innovation as central to restoring NIVEA momentum and sustaining Derma leadership.
Group sales reached €9,852 million in 2025. Consumer sales came to €8,176 million. Derma organic growth was reported at 11.7%. EBIT excluding special factors totaled €1,378 million. EPS was €4.25 [2][3][9][7].
2024 — Record sales peak from prior-year momentum; transition toward normalization in 2025
Beiersdorf reported record sales for FY 2023 in early 2024 and entered 2024–25 with elevated comparables. 2024 was a year of continued high sales from NIVEA and Derma which set a strong prior-year base.
After the 2023 surge, investor perception shifted to watch for sustainability of double-digit growth. Markets began to expect normalization and management prepared to defend margins while investing in innovation.
FY 2023 group sales reached €9,447 million. NIVEA sales exceeded €5.0 billion in 2023 (reported as record, approximately €5.2 billion in 2023 disclosures) with organic growth around 16.2%. These 2023 figures underpinned 2024 positioning and comparables cited in 2025 reporting [20][23][10].
2023 — Powerful double-digit growth driven by NIVEA and Derma; guidance upgrades and strong share performance
2023 marked broad-based double-digit organic growth. Beiersdorf upgraded guidance during the year in mid-2023 and published strong Q3 and nine-month results that drove upward revisions.
The company was perceived as the fastest-growing major beauty firm that year—a growth compounder story driven by NIVEA's renaissance and Derma momentum. Investor confidence pushed the share to new interim highs and above-average market returns.
Group organic sales growth reached 10.8%. Record nominal group sales were reported at approximately €9.5 billion for 2023. NIVEA nominal sales exceeded €5.0 billion in 2023 with organic growth around 16.2%. Year-end share close was reported at €135.70 [16][20][26][23].
2022 — Rebound year with double-digit organic growth from pandemic trough; management continuity established
FY 2022 results showed a strong rebound with double-digit organic growth versus 2021. Management under CEO Vincent Warnery and CFO Astrid Hermann continued to implement strategic priorities.
Market perception shifted from recovery to structural growth, with emphasis on brand revitalization (especially NIVEA) and margin management. Investors started to reward recovery trajectory.
Group sales reached €8,799 million in 2022. Organic sales growth was approximately 10.2%. 2022 was cited as an "excellent year" and foundation for subsequent growth [22][10].
2021 — Leadership changes and stabilization after pandemic disruption
In 2021 Beiersdorf reported recovery from pandemic impacts and introduced CEO Vincent Warnery and CFO Astrid Hermann. Further Executive Board appointments followed (e.g., Grita Loebsack to Executive Board effective January 1, 2022).
Investors focused on management transition and execution risk amid post-pandemic normalization. The narrative was stabilization and transformation under new leadership with emphasis on sustainability and innovation.
Group sales reached €7,627 million in 2021. Organic sales growth was approximately 9.7% [24][10].
Beiersdorf, a German skincare company, leads the mass and premium segments through brands like NIVEA, Eucerin, and La Prairie, spanning skincare, lip care, and wound care. It faces competition from large multinational consumer-goods and cosmetics groups—L'Oréal, Unilever, Procter & Gamble, Estée Lauder, Colgate-Palmolive, and Henkel—that compete primarily on brand strength, distribution reach, and R&D capability. Regional and niche competitors also exert pressure on growth and margins. The company navigates several material headwinds: shifts in consumer demand, volatility in raw-material and input costs, accelerating competitor innovation and pricing actions, and rising regulatory and ESG compliance costs that can reshape product formulations and limit market access.
Beiersdorf operates as a global skincare company with established brands including NIVEA, Eucerin, and La Prairie, competing across mass-market and premium segments against firms like L'Oréal, Unilever, Procter & Gamble, Estée Lauder, and Colgate-Palmolive. The business faces material headwinds from pricing and innovation competition, execution risk around NIVEA's repositioning and premium-tier growth, input cost and foreign exchange volatility, and heightened regulatory and ESG scrutiny regarding ingredients, packaging, and advertising standards across different markets.
| Company | Ticker |
|---|---|
| Unilever PLC | ULVR.LSE |
| The Procter & Gamble Company | PG.NYSE |
| The Estée Lauder Companies Inc. | EL.NYSE |
| Colgate-Palmolive Company | CL.NYSE |
| Henkel AG & Co. KGaA | HEN3.XETRA |
| Kao Corporation | 4452.TSE |
| Church & Dwight Co., Inc. | CHD.NYSE |
Independent and premium skincare brands, along with their distribution partners, that compete directly with Beiersdorf's La Prairie across luxury dermocosmetic channels in specific geographic markets.
Smaller family-owned manufacturers across Europe, Latin America, and Asia produce private-label and niche dermocosmetic products. They compete primarily on price or specialized formulations against established brands like Eucerin and NIVEA within their regional markets.
Receive hand-picked stock recommendations with detailed analyses every week
Start Free Trial| Period | Beiersdorf Aktiengesellschaft | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -2.19% | -3.90% | +2.86% |
| 3M | +0.93% | +2.46% | +5.33% |
| 6M | +10.75% | +7.34% | +12.32% |
| 1Y | -8.17% | -19.28% | -19.56% |
| 3Y | -32.98% | -94.83% | -99.66% |
| 5Y | -10.36% | -69.62% | -76.87% |
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHow the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 18.7 | 1.8 | 2.0 | 16.7 |
| 1Y ago | 14.8 | 1.2 | 2.3 | 9.6 |
| 3Y ago | 23.1 | 2.1 | 3.5 | 30.0 |
| 5Y ago | 21.2 | 1.9 | 12.3 | 12.3 |
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | 1.35% | 0.88% |
| 2025 | 1.00 EUR | 0.84% | |
| 2024 | 1.00 EUR | 0.74% | |
| 2023 | 0.70 EUR | 0.57% | |
| 2022 | 0.70 EUR | 0.74% | |
| 2021 | 0.70 EUR | 0.78% | |
| 2020 | 0.70 EUR | 0.74% | |
| 2019 | 0.70 EUR | 0.76% | |
| 2018 | 0.70 EUR | 0.76% | |
| 2017 | 0.70 EUR | 0.77% | |
| 2016 | 0.70 EUR | 0.88% | |
| 2015 | 0.70 EUR | 0.87% | |
| 2014 | 0.70 EUR | 0.99% | |
| 2013 | 0.70 EUR | 1.03% | |
| 2012 | 0.70 EUR | 1.33% |
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 9.85B | 9.85B | 9.45B | 8.80B | 7.63B |
| Operating income (EBIT) | 1.32B | 1.29B | 1.10B | 1.22B | 980.00M |
| Net income | 939.00M | 912.00M | 736.00M | 755.00M | 638.00M |
| Free cash flow | 373.00M | 794.00M | 424.00M | 249.00M | 580.00M |
| Total assets | 12.85B | 13.01B | 12.63B | 12.35B | 11.30B |
| Equity | 8.60B | 8.47B | 8.32B | 7.79B | 6.87B |
| Net debt | -983.00M | -941.00M | -1.03B | -722.00M | -757.00M |